Jeremy Paull leads Starpharma’s preclinical and clinical development programs, and the Company’s interactions with international regulatory authorities related to these programs. Jeremy previously led Starpharma’s NIH -funded programs, and is responsible for managing successful collaborations with the Company’s many international research and commercial development partners. The development and regulatory team led by Jeremy is responsible for the advancement of the VivaGel® standalone product through late-stage development and commercialisation, the development and commercialisation of the VivaGel® condom product, and the progression of Starpharma’s DEP™ technology, including DEP™ docetaxel, through preclinical and clinical development. Jeremy joined Starpharma in 2001 after working previously at medical technology company, Norwood Abbey, and completing a PhD in pharmacology at Monash University, Melbourne, Australia, prior to that.
